New combo aims to turn untreatable lung tumors into surgical candidates
NCT ID NCT07561983
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining the immunotherapy drug tislelizumab with standard chemotherapy and a targeted chemo-blocking procedure (BACE) can shrink advanced, inoperable stage III non-small cell lung cancer enough to allow surgery. About 39 participants will receive up to 4 cycles of the triple therapy. If their tumors become operable, they may undergo surgery; if not, they will receive standard chemoradiotherapy. The main goal is to see how many patients remain cancer-free after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (an immunotherapy drug) combined with intravenous chemotherapy and a procedure called bronchial artery chemoembolization (BACE)
What this could lead to
If successful, this approach could shrink inoperable lung tumors enough to allow surgery, potentially improving long-term survival.
What could go wrong
This is a small, early-phase trial (39 people) with no control group. The combination may cause significant side effects, and not all participants will become eligible for surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TISLELIZUMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact